Auris Medical Holding AG (EARS.OQ)

About

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsycho... (more)

Buy/Sell

No analyst recommendations are available for .

» Analyst Consensus

Overall

Beta:	--
Market Cap(Mil.):	$32.28
Shares Outstanding(Mil.):	34.33
Dividend:	--
Yield (%):	--

Financials

Latest News about EARS.OQ

BRIEF-Auris Medical Receives Positive Scientific Advice From EMA On Development Plan And Regulatory Pathway For AM-111

* AURIS MEDICAL RECEIVES POSITIVE SCIENTIFIC ADVICE FROM EMA ON DEVELOPMENT PLAN AND REGULATORY PATHWAY FOR AM-111

07 May 2018

BRIEF-Auris Medical Announces Early Repayment Of Part Of Its Loan Facility

* AURIS MEDICAL ANNOUNCES EARLY REPAYMENT OF PART OF ITS LOAN FACILITY

09 Apr 2018

BRIEF-Thomas Meyer Reports 12.6 Pct Stake In Auris Medical As Of March 29

* THOMAS MEYER REPORTS 12.6 PCT STAKE IN AURIS MEDICAL HOLDING AG AS OF MARCH 29, 2018 - SEC FILING‍ Source text: (https://bit.ly/2uJaqwA) Further company coverage:

03 Apr 2018

BRIEF-Auris Regains Compliance With Nasdaq's Minimum Bid Price Requirement

* AURIS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Auris Medical Q4 Loss Per Share CHF 0.10

* AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

22 Mar 2018

BRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing

* AURIS MEDICAL HOLDING AG - ON MARCH 12, AT THE GENERAL MEETING, SHAREHOLDERS APPROVED MERGER BETWEEN CO AND AURIS MEDICAL NEWCO - SEC FILING

14 Mar 2018

BRIEF-Auris Medical Provides Business Update

* AURIS MEDICAL HOLDING AG - PRELIMINARY TOP-LINE DATA FROM TACTT3 TRIAL INDICATE THAT STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT